O

Otsuka Pharmaceutical

Global pharma maker of Abilify

Regional Medical Lead - Great Lakes

Full-TimePosted on 10/21/2026
$209.6k - $313.4k+ Incentive opportunity
Senior, Expert
PharmD, PhD, MD
Remote in USA+3 moreMore locations: Washington, DC, USA | Detroit, MI, USA | Chicago, IL, USA
Remote
Biology & Biotech

About the job

Requirements
  • Seven to ten years of experience providing strategic leadership across therapeutic and cross-functional teams, with demonstrable success partnering with customers and achieving shared goals and outcomes.
  • Ability to develop, communicate, and implement strategy across complex healthcare environments, influence without authority, and mobilize colleagues around shared goals.
  • Understanding of the interconnectivity of health systems and overall patient-care delivery, and ability to develop solutions aimed at improving patient outcomes.
  • Demonstrated ability to comprehend complex scientific, medical, and business issues and use analytical skills to identify key barriers or success factors.
  • Ongoing investment in developing oneself and others to help colleagues achieve their potential, deliver ambitious goals, or achieve excellence.
  • Ability to lead, influence, and collaborate in a matrixed environment regardless of reporting structure, and operate amid ambiguity without a set playbook.
Responsibilities
  • Contribute to the regional strategic business plan addressing regional, local, and customer challenges, issues, and opportunities to improve patient care and outcomes, including alignment on field-activity execution.
  • Partner with the Senior Business Director to establish and manage senior stakeholder and C-suite relationships across the region, understand stakeholder needs, and identify insights and opportunities for medical collaboration.
  • Develop and maintain a deep understanding of regional ecosystems, including health systems, centers of excellence, key influencers, decision makers, and payers, and ensure alignment with Otsuka’s patient-centric strategy and priorities.
  • Serve as the primary medical point of contact for top regional decision makers and influencers to co-create, prioritize, plan, and implement mutually beneficial initiatives aligned with Otsuka’s business priorities.
  • Understand the region’s educational needs from the customer perspective and ensure resources are deployed to meet those needs through product and disease-state approaches.
  • Provide field leadership and managerial oversight to ensure MSLs focus on key institutions, influencers, and decision makers aligned with business priorities; maintain and engage the RML’s own list of influential regional customers through the MSLs.
  • Identify regional evidence-generation needs aligned to local priorities in collaboration with internal stakeholders.
  • Track the region’s customer experience, formally and informally, and use the information to enhance customer engagement and medical strategy.
  • Represent customer needs, insights, and knowledge to senior leadership and internal partners, including disease-area strategy, brand medical, and health outcomes research teams, to advance shared goals with customers.
  • Identify and facilitate training for regional colleagues and others to ensure team members are competent in the evolving market and healthcare landscape.
  • Develop and track metrics across medical-portfolio activities, including performance, outcomes, and collaboration; identify opportunities through analytics and ongoing business reviews and adapt medical plans using agile approaches as needed.
  • Provide coaching and feedback to the MSLs within the region.
  • Create and foster a collaborative, patient-centric culture centered on experimentation and innovation, with a team that is curious about possibilities and empowered to act.
Desired Qualifications
  • An advanced degree in Pharmacy, Medicine, or Biological Sciences, such as a Pharm.D., M.D., D.O., or Ph.D., is strongly preferred.

About the company

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT's August 2026 two-year data supports a supplemental FDA approval filing.
  • Transcend acquisition closed June 15, 2026, adding a differentiated neuropsychiatry pipeline.
  • Paradise renal denervation gained Japan insurance coverage March 1, 2026, accelerating sales.

What critics are saying

  • Abilify patents keep expiring through 2027, pressuring a legacy revenue engine.
  • Otsuka v Sun Pharma in Australia threatens ABILIFY MAINTENA patent-extension protection.
  • Transcend's PTSD asset, TSND-201, reaches Phase 3 completion only in late 2027.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs pharmaceuticals, devices, and diagnostics across renal, psychiatric, and cardiovascular care.
  • SIMTRIYO, approved July 23, 2026, is the first approved NDSRI for ADHD.
  • VOYXACT delivered 24-month eGFR stabilization, strengthening Otsuka's IgA nephropathy leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Tuition Reimbursement
  • Student Loan Assistance
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Otsuka US
Sep 20th, 2026
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments | Otsuka US

Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions.

Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.